An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
Recruiting now · Phase 3
Conditions studied: Hidradenitis Suppurativa
In brief
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of remibrutinib (LOU064) in adult participants with moderate to severe hidradenitis suppurativa (HS) who have completed either of the preceding Phase 3 studies, CLOU064J12301 or CLOU064J12302.
Key facts
- Study ID
- NCT07665437
- Run by
- Novartis Pharmaceuticals
- People needed
- 710
- Starts
- 2026-07-10
- Expected to finish
- 2031-10-27
- Last updated by the study team
- 2026-07-15
Who can join
Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Caba, Buenos Aires, Argentina (enrolling)
- Novartis Investigative Site — CABA, Argentina (enrolling)
- Novartis Investigative Site — Sydney, New South Wales, Australia (enrolling)
- Novartis Investigative Site — Melbourne, Victoria, Australia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.